The Impact of the Commensal Microbiome on Cancer Progression and Therapy Response

 Sunday, May 8, 2022     12:30 PM – 2:30 PM ET     Room B113–116

The Impact of the Commensal Microbiome on Cancer Progression and Therapy Response

Chairs

• Melanie R. Rutkowski, Univ. of Virginia
• Irving Allen, Col. of Vet. Med.. Virginia Tech

Speakers

• Kaiting Yang, Univ. of Chicago, Suppression of local IFN-I by commensal microbiota-derived butyrate impairs antitumor effects of ionizing radiation
• Qingsheng Li, Univ. of Louisville, Dietary low-fiber promotes resistance to immune checkpoint inhibitor immunotherapy in the LSL-Kras^G12D Lung Cancer Model
• Romina E. Araya, NCI, NIH, Neutrophil dynamics in the tumor microenvironment determines therapy efficacy and is regulated by microbiota
• Liangliang Wang, Univ. of Chicago, Lactobacillus rhamnosus GG re-shapes gut microbiota and triggers STING-type I IFN-dependent antitumor immunity
• Mitchell Thomas McGinty, Univ. of Virginia, Absence of Toll-like receptor 5 confers survival in mice bearing ovarian tumors treated with anti-PD-L1
• Qingsheng Li, Univ. of Louisville, Resistance to Anti-PD-1 Therapy is mediated via the Microbiota-Th17-Prostoglandin E2 Axis in the LSLKras^G12D Lung Cancer Model
• Khiem C. Lam, NCI, NIH, Tumor-intrinsic factors dictate beneficial effect of microbiota-based therapies